AI-Driven Bioprinting Emerges as a High-Conviction Investment Theme as Corporate AI Spending Surpasses $252 Billion
AI investment in bioprinting has reached a historic inflection point with corporate AI spending totaling $252.3 billion in 2024. The U.S. leads global AI investment with $109.1 billion, enabling faster commercialization of AI-integrated bioprinting technologies. Major venture capital rounds validate the sector, with companies developing AI-powered tissue therapies for drug discovery, regenerative medicine, and personalized treatments. The competitive landscape is intensifying with key players securing significant funding and strategic pharma partnerships.